Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials

Biohaven Ltd. (NYSE:BHVN) is one of the 10 Stocks Paying Off Big Time.

Biohaven saw its share prices climb by 14.22 percent on Monday to finish at $15.50 apiece, as investors resumed buying positions ahead of the initiation of two clinical studies by the end of the month.

Based on its key milestone calendar, Biohaven Ltd. (NYSE:BHVN) is set to initiate clinical studies for its BHV-1510 for advanced or metastatic epithelial tumors, as well as the BHV-1530 for urothelial cancer and other tumors, by the end of the month.

Photo by Tima Miroshnichenko on Pexels

It is also planning to begin pivotal studies for BHV-1400 for the treatment of IgAN, or Berger disease, as well as BHV-1300 for Graves’ disease, in the middle of the year.

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.

In the first quarter of the year, it was able to slash its net losses by 41 percent to $130.5 million from $221.7 million in the same period last year. It has yet to generate revenues as of the period.

While we acknowledge the risk and potential of BHVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BHVN and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1